• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Novo Nordisk Agrees to Cap Insulin Prices, but Some Aren't Impressed


The pharmaceutical leader's move comes after the American Diabetes Association asked Congress to investigate rising insulin prices.

Soaring insulin prices have been in the news all year. Democratic presidential hopeful Senator Bernie Sanders, I-Vermont, sounded the alarm, as have leading physicians and the American Diabetes Association, (ADA) which passed a resolution asking Congress to investigate.

So what was the reaction when Novo Nordisk, one of 3 leading insulin makers, announced this week it would cap price increases to single digits?

John Rother, executive director of the Campaign for Sustainable Rx Pricing, was not impressed.

“The prescription drug market is clearly broken when limiting yearly price increases to 10% is considered big hearted,” he said in a statement. “Novo Nordisk’s announcement is insulting to the millions of patients that have already endured prescription price hikes for years, and this announcement is proof there is no end in sight.”

Outcry over insulin price increases has been growing at professional meetings over the past year and led the ADA to demand action. The group cited not only increases of 700% since 1996, but also the fact that the major insulin manufacturers seem to raise prices at the same time.

In a blog post dated November 30, 2016, which did not get attention until this week, Novo Nordisk President Jakob Riis wrote that the company will pledge to keep out-of-pocket costs low for consumers through patient assistance programs and by making cheaper forms of insulin available. Riis also pledged to simplify the complex pricing structure, which involves ever-increasing rebates to pharmacy benefit managers (PBMs).

Riis asserts that the system means that while list prices keep climbing, net prices to drug makers have not gone up accordingly. But Riis acknowledged that the proliferation of high-deductible plans means that too many patients who rely on insulin to stay alive must fork over huge sums before their coverage kicks in.

“In our view, high-deductible plans are becoming a greater part of the affordability issue requiring attention,” he wrote.

Related Videos
Ian Neeland, MD
Chase D. Hendrickson, MD, MPH
Steven Coca, MD, MS, Icahn School of Medicine, Mount Sinai
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Susan Spratt, MD, senior medical director, Duke Population Health Management Office, associate professor of medicine, division of Endocrinology, Metabolism, and Nutrition,
Stephen Nicholls, MD, Monash University and Victorian Heart Hospital
Amal Agarwal, DO, MBA
Dr Robert Groves
Dr Robert Groves
Related Content
© 2024 MJH Life Sciences
All rights reserved.